Clinical trial Recruiting at 1 site Interventional Ages 18 to 80

Cold atmospheric plasma plus endovascular treatment for diabetic foot ulcers with blocked lower‑leg arteries

Official title: Efficacy and Safety of Cold Atmospheric Plasma Combined With Endovascular Intervention in Patients With Diabetic Foot Ulcers and Lower Extremity Arterial Occlusion: a Randomized, Double-blind, Placebo-controlled Clinical Trial

Run by Shenyang Medical College · NCT07073040 · Data updated 2026-11-12

This will test whether adding cold atmospheric plasma after successful endovascular angioplasty helps heal diabetic foot ulcers in adults with lower‑leg arterial blockages.

More Diabetic Foot Ulcer (DFU) trials

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment86 (estimated)
SponsorShenyang Medical College
Academic / other
Locations1 site (Anshan, Liaoning)
StatusRecruiting
StartedJuly 22, 2025
Main results expectedApril 10, 2026
Study endsMay 6, 2026
Registry record updatedJanuary 30, 2026
Trial IDNCT07073040 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–80 with type 1 or 2 diabetes, an HbA1c ≤10%, a chronic foot ulcer (≥3 weeks) classified as Wagner‑Armstrong 1D or 2D, documented infrapopliteal stenosis/occlusion who have received successful infrapopliteal balloon angioplasty, and who provide informed consent are ideal candidates.

Probably not a fit

Patients receiving other local advanced wound therapies (for example vacuum‑assisted closure or maggot therapy), those who do not achieve successful revascularization, or those with wounds unsuitable for topical CAP application are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study enrolls adults with diabetes who have chronic foot ulcers and documented infrapopliteal arterial stenosis or occlusion who undergo successful infrapopliteal balloon angioplasty. After confirming arterial patency by intraoperative angiography, participants receive either cold atmospheric plasma treatment to the ulcer or a sham procedure in addition to standard wound care. The goal is to determine whether the local application of cold atmospheric plasma improves microvascular perfusion and accelerates wound healing beyond revascularization alone. Outcomes will include wound healing measures and safety endpoints over a defined follow‑up period.

Why it matters

Potential benefit: If successful, the combined approach could speed ulcer healing, reduce the need for amputations, and improve limb salvage in people with ischemic diabetic foot ulcers.

How similar studies have gone: Small pilot studies and early clinical reports suggest cold atmospheric plasma can promote wound healing, but combining CAP with endovascular revascularization is a relatively novel approach without large randomized trial confirmation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged 18-80 years, with a diagnosis of type 1 or type 2 diabetes and diabetic foot ulcer; glycated hemoglobin (HbA1c) ≤ 10%.
* Presence of at least one chronic foot ulcer persisting for at least three weeks, with no signs of healing after standard-of-care treatment based on current clinical guidelines. The ulcer must be classified as Wagner-Armstrong grade 1D or 2D (Wagner: superficial ulcer \[grade 1\] or ulcer extending to tendon \[grade 2\]; Armstrong: presence of both ischaemia and infection \[stage D\]).
* Documented infrapopliteal arterial stenosis or occlusion by vascular ultrasound and/or CT angiography (CTA), meeting indications for revascularization. All enrolled patients must have received successful infrapopliteal balloon angioplasty, with intraoperative angiography confirming target artery patency.
* Provision of written informed consent.

Exclusion Criteria:

* Concurrent treatment of the wound with local vacuum therapy or maggot therapy.
* Undergoing dialysis.
* Use of local active antibiotics.
* Treatment with platelet-rich fibrin.
* Women of childbearing potential without effective contraception, or women who are actively breastfeeding.
* Presence of other severe organ dysfunction, with an expected survival of less than six months.
* Participation in another clinical trial within the past three months or currently enrolled in another clinical trial.

Where it's running

  • Ansteel General Hospital
    Anshan, Liaoning, China
    Recruiting

Study contacts

  • Principal investigator: Lin Tao, MM — Shenyang Medical College
  • Study coordinator: Yun-En Liu, MD
  • Email: lye9901@163.com
  • Phone: 86-24-62215130

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.